GRACEcast

By Howard (Jack) West, MD

Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Edu... more

Download on the App Store

Download on the App Store

Get it on Google Play

FAQs about GRACEcast:

How many episodes does GRACEcast have?

The podcast currently has 625 episodes available.

GRACEcast episodes:

July 02, 2013 Dr. Geoffrey Oxnard: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?
Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.
...more
3min
June 27, 2013 Could BRAF be a new target in NSCLC?
Drs. Nate Pennell, Mary Pinder, and Jack West discuss an encouraging study of dabrafenib, a BRAF inhibitor, for the limited number of NSCLC patients with a BRAF V600E mutation.
...more
5min
June 21, 2013 Are molecular markers just for NSCLC?
Dr. Mary Pinder of Moffitt Cancer Center reviews the CUSTOM trial, in which the study of molecular markers was expanded to patients with small cell lung cancer and thymic carcinomas.
...more
3min
June 21, 2013 Dr. David Spigel: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Dr. David Spigel gives his view on more widespread availability of new mutation tests, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for other lung cancer subtypes.
...more
3min
June 21, 2013 Dr. Heather Wakelee on "Which molecular marker tests do you seek?"
Dr. Heather Wakelee, from Stanford University, describes which molecular markers she seeks for NSCLC patients.
...more
2min
June 19, 2013 Is nindetanib a new agent worthy of becoming a new treatment for advanced NSCLC?
Dr. Nate Pennell from Cleveland Clinic reviews the LUME Lung-1 trial presented by Reck at ASCO 2013, of Taxotere with or without nindetanib (BIBF-1120), an anti-angiogenic multikinase inhibitor, in advanced NSCLC.
...more
6min
June 19, 2013 Can we improve on XALKORI? New agents for patients with an ALK-1 rearrangement
Dr. Mary Pinder reviews promising studies from ASCO 2013 on second gen. ALK inhibitors LDK-378, CH5424802, and AP26113 in patients with ALK-positive advanced NSCLC, including impressive activity in crizotinib-refractory patients and those with brain mets.
...more
7min
June 19, 2013 Can we harness our immune system to fight NSCLC?
Drs. Mary Pinder, Nate Pennell, and Jack West discuss promising work on immune checkpoint inhibitors such as MPPL-3280A, an anti-PDL1 immune-based therapy, and anti-PD1 therapy nivolumab, in advanced NSCLC.
...more
9min
June 19, 2013 Can addition of a "heat shock protein inhibitor" to standard chemo improve outcomes in advanced NSCLC?
Drs. Mary Pinder, Nate Pennell, and Jack West discuss the results presented at ASCO 2013 of the GALAXY-1 trial of the HSP90 inhibitor ganetespib combined with Taxotere (docetaxel) as second line therapy for advanced NSCLC.
...more
7min
June 15, 2013 Dr. Larry Einhorn: What is Your Opinion of Patients and Caregivers Searching the Internet for Information?
Dr. Larry Einhorn, Distinguished Professor of Medicine at Indiana Univ and former ASCO president, discusses the trend of patients consulting Dr.Google - finding information of varied quality on the internet.
...more
2min

FAQs about GRACEcast:

How many episodes does GRACEcast have?

The podcast currently has 625 episodes available.